Approval for Seqirus flu vaccine
Seqirus has announced European approval of its new cell-based quadrivalent influenza vaccine.
Read More
Tag: fluxelvax
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
